Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Treatment Interruption of Natalizumab

Next Previous
Trial Profile

Randomized Treatment Interruption of Natalizumab

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary) ; Glatiramer acetate; Interferon beta-1a; Methylprednisolone
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms RESTORE
  • Sponsors Biogen

Most Recent Events

  • 19 Sep 2020 Results from RESTORE (n=175) developing model for efficacy of natalizumab extended interval dosing and retrospectively validating Models using data from REFINE, published in the Journal of Clinical Pharmacology
  • 12 Oct 2018 Results assessing relationship between Serum neurofilament light (sNfL) dynamics and radiologic disease activity in retrospective analysis performed on a subset of n=65 multiple sclerosis patients, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
  • 15 Sep 2017 Results assessing reversibility of natalizumab-mediated changes in pharmacokinetics/pharmacodynamics using patient data from AFFIRM and RESTORE trials published in the Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top